No­vavax takes pro­tein-based Covid-19 vac­cine over­seas, ask­ing for an ap­proval in the UK

Just af­ter an on­slaught of man­u­fac­tur­ing is­sues last week and sub­mit­ting their Covid-19 vac­cine to the WHO for re­view last month, No­vavax is go­ing across the sea and tak­ing its pro­tein-based Covid-19 vac­cine up with the crown.

The com­pa­ny filed for mar­ket­ing au­tho­riza­tion ap­proval with the MHRA in the UK, No­vavax said this morn­ing in a state­ment.

As for a sub­mis­sion to the FDA, No­vavax said that they plan to have the ap­pli­ca­tion in by year’s end. The Mary­land biotech has de­layed fil­ing with the FDA sev­er­al times, spark­ing crit­i­cism from an­a­lysts as cred­i­bil­i­ty has worn thin.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER